Clinical Trial

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Study acronym: ANTELOPE
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is an open-label randomized, controlled, multicenter, phase II trial with two arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in a 1:1 manner to investigate the efficiency of atezolizumab, carboplatin and nab-paclitaxel (Arm A) versus pembrolizumab, cis-/carboplatin and pemetrexed (Arm B) as first-line treatment.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-01-18; most recent amendment 2026-03-06.
Status change: Recruiting → Active, Not Recruiting 2026-03-06
Status change: Not Yet Recruiting → Recruiting 2023-11-01
Trial Details
NCT Number NCT05689671
Lead Sponsor Nikolaj Frost MD
Collaborators: Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Conditions Non-Small Cell Lung Cancer Metastatic
Enrollment 136 participants
Start Date 2023-12-06
Primary Completion 2026-03-05 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-10